Table 2.
Groups | Healthy donor (n = 47) | Stage I (n = 25) | Stage II (n = 26) | Stage III (n = 42) | Stage IV (n = 9) |
---|---|---|---|---|---|
CSE1L-positive, cases (%) | 4 (8.5) | 9 (36.0)* | 15 (57.7)‡ | 30 (71.4)¶ | 8 (88.9)** |
CEA-positive, cases (%) | Not assayed | 4 (16.0) | 11 (42.3) | 20 (47.6) | 7 (77.8) |
CSE1L or CEA-positive, cases (%) | Not assayed | 12 (48.0)† | 17 (65.4)§ | 37 (88.1)∥ | 9 (100)†† |
P = 0.021, compared with that of CEA-positive cases in stage I group.
P = 0.0025, compared with that of CEA-positive cases in stage I group.
P = 0.043, compared with that of CEA-positive cases in stage II group.
P = 0.011, compared with that of CEA-positive cases in stage II group.
P = 0.0009, compared with that of CEA-positive cases in stage III group.
P = 0.000004, compared with that of CEA-positive cases in stage III group.
P = 0.346, compared with that of CEA-positive cases in stage IV group.
P = 0.169, compared with that of CEA-positive cases in stage IV group.